RhumbLine Advisers
CTKB icon

RhumbLine Advisers’s Cytek Biosciences CTKB Stock Holding History

RhumbLine Advisers’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Sell
153,225
-101,364
-40% -$433K ﹤0.01% 2559
2026
Q1 		$1.11M Buy
254,589
+4,649
+2% +$21.9K ﹤0.01% 2143
2025
Q4 		$1.26M Sell
249,940
-30,427
-11% -$141K ﹤0.01% 2110
2025
Q3 		$973K Sell
280,367
-2,284
-0.8% -$8.57K ﹤0.01% 2261
2025
Q2 		$961K Sell
282,651
-13,633
-5% -$45.4K ﹤0.01% 2268
2025
Q1 		$1.19M Buy
296,284
+1,745
+0.6% +$9.04K ﹤0.01% 2090
2024
Q4 		$1.91M Buy
294,539
+14
+0% +$83 ﹤0.01% 1901
2024
Q3 		$1.63M Sell
294,525
-60,911
-17% -$345K ﹤0.01% 2016
2024
Q2 		$1.98M Buy
355,436
+18,124
+5% +$109K ﹤0.01% 1891
2024
Q1 		$2.26M Buy
337,312
+9,682
+3% +$76.6K ﹤0.01% 1849
2023
Q4 		$2.99M Buy
327,630
+5,638
+2% +$35.5K ﹤0.01% 1702
2023
Q3 		$1.78M Buy
321,992
+31,570
+11% +$253K ﹤0.01% 1912
2023
Q2 		$2.48M Buy
290,422
+141,055
+94% +$1.27M ﹤0.01% 1787
2023
Q1 		$1.37M Buy
149,367
+6,804
+5% +$73.2K ﹤0.01% 1998
2022
Q4 		$1.46M Buy
142,563
+1,845
+1% +$24.8K ﹤0.01% 1947
2022
Q3 		$2.07M Buy
140,718
+11,751
+9% +$153K ﹤0.01% 1741
2022
Q2 		$1.38M Buy
128,967
+32,689
+34% +$325K ﹤0.01% 1960
2022
Q1 		$1.04M Buy
96,278
+81,455
+550% +$1.1M ﹤0.01% 2117
2021
Q4 		$242K Buy
14,823
+3,062
+26% +$64.1K ﹤0.01% 2775
2021
Q3 		$252K Buy
+11,761
New +$277K ﹤0.01% 2836

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers's CTKB Position: Q2 2026 in Review

RhumbLine Advisers reduced its Cytek Biosciences (CTKB) stake by 40% in Q2 2026, selling an estimated $433K and leaving 153,225 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

RhumbLine Advisers first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.99M in Q4 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • RhumbLine Advisers held 153,225 shares of Cytek Biosciences worth $679K as of Q2 2026.
  • RhumbLine Advisers sold 101,364 Cytek Biosciences shares in Q2 2026, an estimated $433K.
  • Cytek Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2559 holding.
  • RhumbLine Advisers first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • RhumbLine Advisers's Cytek Biosciences position peaked at $2.99M in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.